AI models for the identification of prognostic and predictive biomarkers in lung cancer: a systematic review and meta-analysis
Open Access
- 26 February 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1424647
Abstract
Introduction: This systematic review and meta-analysis aim to evaluate the efficacy of artificial intelligence (AI) models in identifying prognostic and predictive biomarkers in lung cancer. With the increasing complexity of lung cancer subtypes and the need for personalized treatment strategies, AI-driven approaches offer a promising avenue for biomarker discovery and clinical decision-making.Methods: A comprehensive literature search was conducted in multiple electronic databases to identify relevant studies published up to date. Studies investigating AI models for the identification of prognostic and predictive biomarkers in lung cancer were included. Data extraction, quality assessment, and meta-analysis were performed according to PRISMA guidelines.Results: A total of 34 studies met the inclusion criteria, encompassing diverse AI methodologies and biomarker targets. AI models, particularly deep learning and machine learning algorithms demonstrated high accuracy in predicting biomarker status. Most of the studies developed models for the prediction of EGFR, followed by PD-L1 and ALK biomarkers in lung cancer. Internal and external validation techniques confirmed the robustness and generalizability of AI-driven predictions across heterogeneous patient cohorts. According to our results, the pooled sensitivity and pooled specificity of AI models for the prediction of biomarkers of lung cancer were 0.77 (95% CI: 0.72 – 0.82) and 0.79 (95% CI: 0.78 – 0.84).Conclusion: The findings of this systematic review and meta-analysis highlight the significant potential of AI models in facilitating non-invasive assessment of prognostic and predictive biomarkers in lung cancer. By enhancing diagnostic accuracy and guiding treatment selection, AI-driven approaches have the potential to revolutionize personalized oncology and improve patient outcomes in lung cancer management. Further research is warranted to validate and optimize the clinical utility of AI-driven biomarkers in large-scale prospective studies.Keywords
This publication has 53 references indexed in Scilit:
- Predicting EGFR mutation status by a deep learning approach in patients with non-small cell lung cancer brain metastasesJournal of Neuro-Oncology, 2022
- Detailed identification of epidermal growth factor receptor mutations in lung adenocarcinoma: Combining radiomics with machine learningMedical Physics, 2020
- Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning AlgorithmsMolecular Imaging and Biology, 2020
- Predictive models for patients with lung carcinomas to identify EGFR mutation status via an artificial neural network based on multiple clinical informationJournal of Cancer Research and Clinical Oncology, 2019
- Machine learning-based radiomics strategy for prediction of cell proliferation in non-small cell lung cancerEuropean Journal of Radiology, 2019
- Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)Advances in Therapy, 2019
- Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modelingEuropean Radiology, 2019
- Early detection of lung cancer biomarkers through biosensor technology: A reviewJournal of Pharmaceutical and Biomedical Analysis, 2019
- Application of artificial neural network model combined with four biomarkers in auxiliary diagnosis of lung cancerMedical & Biological Engineering & Computing, 2016
- Development of an optimized multi-biomarker panel for the detection of lung cancer based on principal component analysis and artificial neural network modelingExpert Systems with Applications, 2012